Oculis Launches Genotype Trial for Dry Eye Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Trial Initiation: Oculis has announced the launch of the first genotype-based registrational trial, PREDICT-1, in dry eye disease (DED), with the first patient randomized, marking a significant advancement in precision medicine treatment.
- Patient Recruitment: The trial plans to enroll approximately 160 patients, with about two-thirds carrying the specific TNFR1 genotype, aiming to evaluate the efficacy and safety of Licaminlimab, particularly in genotype-positive patients.
- Market Demand: Approximately 10 million patients in the U.S. suffer from moderate to severe DED, with current treatment methods showing low efficacy, as only 13% of patients experience sustained relief, highlighting the urgent need for targeted therapies.
- Therapeutic Potential: Licaminlimab, an anti-TNFα eye drop, if approved, is expected to significantly improve symptoms for DED patients through a precision medicine approach, potentially transforming the current treatment paradigm.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OCS
Wall Street analysts forecast OCS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.210
Low
29.00
Averages
40.00
High
55.00
Current: 11.210
Low
29.00
Averages
40.00
High
55.00
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oculis Holding AG Shares Plunge 23% After Trial Failures
- Trial Failures: Oculis Holding AG's lead product OCS-01 failed to meet the primary endpoint in Phase 3 DIAMOND trials for diabetic macular edema, resulting in a 23% drop in share value in a single session, causing significant losses for investors.
- Resource Redirection: The company announced it would abandon the FDA filing for the DME indication and redirect resources to other pipeline candidates, a strategic shift that may impact future revenue streams and market positioning.
- Market Potential Lost: OCS-01 was considered a key candidate targeting a multi-billion-dollar market, and the trial failures mean Oculis has lost a critical competitive opportunity in this space, potentially negatively affecting its long-term growth outlook.
- Legal Investigation Initiated: Levi & Korsinsky LLP is investigating whether Oculis adequately disclosed risks to shareholders prior to the stock's significant decline, and if misconduct is found, it could lead to further legal and financial repercussions for the company.
See More
Oculis Launches Genotype Trial for Dry Eye Disease
- Trial Initiation: Oculis has announced the launch of the first genotype-based registrational trial, PREDICT-1, in dry eye disease (DED), with the first patient randomized, marking a significant advancement in precision medicine treatment.
- Patient Recruitment: The trial plans to enroll approximately 160 patients, with about two-thirds carrying the specific TNFR1 genotype, aiming to evaluate the efficacy and safety of Licaminlimab, particularly in genotype-positive patients.
- Market Demand: Approximately 10 million patients in the U.S. suffer from moderate to severe DED, with current treatment methods showing low efficacy, as only 13% of patients experience sustained relief, highlighting the urgent need for targeted therapies.
- Therapeutic Potential: Licaminlimab, an anti-TNFα eye drop, if approved, is expected to significantly improve symptoms for DED patients through a precision medicine approach, potentially transforming the current treatment paradigm.
See More
Oculis Highlights Breakthrough Therapies at Goldman Sachs Healthcare Conference
- Drug Development Progress: Oculis' Privosegtor has received Breakthrough Therapy designation from the FDA and Priority Medicines designation from the EMA, targeting optic neuritis in the PIONEER registration program, which is expected to address a market opportunity exceeding $7 billion, showcasing the company's strong potential in neuro-ophthalmology.
- Precision Medicine Innovation: Licaminlimab is being evaluated in the PREDICT-1 registrational trial as the first genotype-based precision medicine for dry eye disease, marking Oculis' innovative efforts in treating dry eye, which could significantly enhance patient quality of life.
- Financial Strength: With a robust balance sheet and advanced pipeline, Oculis is poised to deliver several pivotal clinical trial results with current funding, further solidifying its position in the biopharmaceutical industry.
- Investor Engagement: Oculis will hold one-on-one investor meetings at the Goldman Sachs Healthcare Conference on June 9, showcasing its innovative product portfolio and aiming to attract potential investors, thereby enhancing market confidence through transparent communication.
See More
Oculis Under Investigation for Securities Violations Affecting Shareholder Rights
- Investigation Launched: The Schall Law Firm has initiated an investigation into Oculis Holding AG regarding potential violations of securities laws, focusing on whether the company issued false or misleading statements that may have harmed shareholder rights.
- Clinical Trial Failures: Oculis claimed its Phase 3 DIAMOND trials were “advancing as planned,” but announced on May 29, 2026, that both trials failed to meet their primary endpoints, directly impacting the company's future drug application prospects.
- FDA Filing Abandonment: Following the disappointing DIAMOND trial results, Oculis has decided not to pursue an FDA filing for its drug candidate, a move that could lead to decreased investor confidence and negatively affect the company's stock price.
- Shareholder Rights Advocacy: The Schall Law Firm encourages affected shareholders to reach out to discuss their rights, demonstrating a commitment to investor protection and potentially prompting more shareholders to engage in litigation for compensation.
See More
Nan Fung Group Reduces Oculis Stake
- Stake Reduction Details: In Q1 2026, Nan Fung Group sold 163,957 shares of Oculis, valued at approximately $4.3 million, leaving a remaining stake of 350,745 shares worth about $9.3 million, making it the fourth-largest position in their portfolio, indicating a cautious approach towards Oculis.
- Stock Price Analysis: Following the failure of two critical Phase 3 trials in May 2026, Oculis's stock plummeted roughly 43% over the past year, significantly underperforming the S&P 500 by approximately 67 percentage points, reflecting market concerns about its future prospects.
- Financial Health Assessment: Oculis exited Q1 2026 with $277.6 million in cash, while burning through $30 to $37 million per quarter in operating expenses; management claims this runway extends into the second half of 2029, provided spending is effectively controlled, offering a buffer for future R&D.
- Future Development Outlook: Despite losing a lead late-stage asset, Oculis is still advancing its Privosegtor and Licaminlimab programs, and investors should closely monitor updates on Privosegtor's clinical data to assess its potential impact on the stock price.
See More
Nan Fung Group Reduces Oculis Stake Amid Challenges
- Share Reduction Details: Nan Fung Group reduced its Oculis stake by 163,957 shares in Q1 2026, valued at approximately $4.3 million, indicating a routine portfolio adjustment rather than a loss of confidence in the company.
- Holding Value Analysis: At quarter-end, Nan Fung retained 350,745 shares of Oculis, valued at $9.3 million, representing 7.7% of its total AUM, highlighting Oculis's significance in its investment portfolio.
- Company Financial Status: Oculis has a market capitalization of $677 million, facing a net loss of $94.6 million; however, as of March 31, 2026, it reported $277.6 million in cash and short-term investments, providing a runway into the second half of 2029.
- R&D Progress and Challenges: Following the failure of its Phase 3 trials for OCS-01 in May 2026, Oculis's stock price has dropped about 43% over the past year, prompting a shift in focus to its remaining programs, Privosegtor and Licaminlimab, with investors needing to watch for upcoming data updates.
See More
Oculis Holding AG Shares Plunge 23% After Trial Failures
- Trial Failures: Oculis Holding AG's lead product OCS-01 failed to meet the primary endpoint in Phase 3 DIAMOND trials for diabetic macular edema, resulting in a 23% drop in share value in a single session, causing significant losses for investors.
- Resource Redirection: The company announced it would abandon the FDA filing for the DME indication and redirect resources to other pipeline candidates, a strategic shift that may impact future revenue streams and market positioning.
- Market Potential Lost: OCS-01 was considered a key candidate targeting a multi-billion-dollar market, and the trial failures mean Oculis has lost a critical competitive opportunity in this space, potentially negatively affecting its long-term growth outlook.
- Legal Investigation Initiated: Levi & Korsinsky LLP is investigating whether Oculis adequately disclosed risks to shareholders prior to the stock's significant decline, and if misconduct is found, it could lead to further legal and financial repercussions for the company.
See More
Oculis Launches Genotype Trial for Dry Eye Disease
- Trial Initiation: Oculis has announced the launch of the first genotype-based registrational trial, PREDICT-1, in dry eye disease (DED), with the first patient randomized, marking a significant advancement in precision medicine treatment.
- Patient Recruitment: The trial plans to enroll approximately 160 patients, with about two-thirds carrying the specific TNFR1 genotype, aiming to evaluate the efficacy and safety of Licaminlimab, particularly in genotype-positive patients.
- Market Demand: Approximately 10 million patients in the U.S. suffer from moderate to severe DED, with current treatment methods showing low efficacy, as only 13% of patients experience sustained relief, highlighting the urgent need for targeted therapies.
- Therapeutic Potential: Licaminlimab, an anti-TNFα eye drop, if approved, is expected to significantly improve symptoms for DED patients through a precision medicine approach, potentially transforming the current treatment paradigm.
See More
Oculis Highlights Breakthrough Therapies at Goldman Sachs Healthcare Conference
- Drug Development Progress: Oculis' Privosegtor has received Breakthrough Therapy designation from the FDA and Priority Medicines designation from the EMA, targeting optic neuritis in the PIONEER registration program, which is expected to address a market opportunity exceeding $7 billion, showcasing the company's strong potential in neuro-ophthalmology.
- Precision Medicine Innovation: Licaminlimab is being evaluated in the PREDICT-1 registrational trial as the first genotype-based precision medicine for dry eye disease, marking Oculis' innovative efforts in treating dry eye, which could significantly enhance patient quality of life.
- Financial Strength: With a robust balance sheet and advanced pipeline, Oculis is poised to deliver several pivotal clinical trial results with current funding, further solidifying its position in the biopharmaceutical industry.
- Investor Engagement: Oculis will hold one-on-one investor meetings at the Goldman Sachs Healthcare Conference on June 9, showcasing its innovative product portfolio and aiming to attract potential investors, thereby enhancing market confidence through transparent communication.
See More
Oculis Under Investigation for Securities Violations Affecting Shareholder Rights
- Investigation Launched: The Schall Law Firm has initiated an investigation into Oculis Holding AG regarding potential violations of securities laws, focusing on whether the company issued false or misleading statements that may have harmed shareholder rights.
- Clinical Trial Failures: Oculis claimed its Phase 3 DIAMOND trials were “advancing as planned,” but announced on May 29, 2026, that both trials failed to meet their primary endpoints, directly impacting the company's future drug application prospects.
- FDA Filing Abandonment: Following the disappointing DIAMOND trial results, Oculis has decided not to pursue an FDA filing for its drug candidate, a move that could lead to decreased investor confidence and negatively affect the company's stock price.
- Shareholder Rights Advocacy: The Schall Law Firm encourages affected shareholders to reach out to discuss their rights, demonstrating a commitment to investor protection and potentially prompting more shareholders to engage in litigation for compensation.
See More
Nan Fung Group Reduces Oculis Stake
- Stake Reduction Details: In Q1 2026, Nan Fung Group sold 163,957 shares of Oculis, valued at approximately $4.3 million, leaving a remaining stake of 350,745 shares worth about $9.3 million, making it the fourth-largest position in their portfolio, indicating a cautious approach towards Oculis.
- Stock Price Analysis: Following the failure of two critical Phase 3 trials in May 2026, Oculis's stock plummeted roughly 43% over the past year, significantly underperforming the S&P 500 by approximately 67 percentage points, reflecting market concerns about its future prospects.
- Financial Health Assessment: Oculis exited Q1 2026 with $277.6 million in cash, while burning through $30 to $37 million per quarter in operating expenses; management claims this runway extends into the second half of 2029, provided spending is effectively controlled, offering a buffer for future R&D.
- Future Development Outlook: Despite losing a lead late-stage asset, Oculis is still advancing its Privosegtor and Licaminlimab programs, and investors should closely monitor updates on Privosegtor's clinical data to assess its potential impact on the stock price.
See More
Nan Fung Group Reduces Oculis Stake Amid Challenges
- Share Reduction Details: Nan Fung Group reduced its Oculis stake by 163,957 shares in Q1 2026, valued at approximately $4.3 million, indicating a routine portfolio adjustment rather than a loss of confidence in the company.
- Holding Value Analysis: At quarter-end, Nan Fung retained 350,745 shares of Oculis, valued at $9.3 million, representing 7.7% of its total AUM, highlighting Oculis's significance in its investment portfolio.
- Company Financial Status: Oculis has a market capitalization of $677 million, facing a net loss of $94.6 million; however, as of March 31, 2026, it reported $277.6 million in cash and short-term investments, providing a runway into the second half of 2029.
- R&D Progress and Challenges: Following the failure of its Phase 3 trials for OCS-01 in May 2026, Oculis's stock price has dropped about 43% over the past year, prompting a shift in focus to its remaining programs, Privosegtor and Licaminlimab, with investors needing to watch for upcoming data updates.
See More
